Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
HOME > BUSINESS
BUSINESS
- Toyama Chemical Starts Commercial Production at Newly-Established Plant for Injectables
August 6, 2013
- Eisai Sales Up 5.0%, Helped by Growth of New Products
August 5, 2013
- Sales of Eisai’s Obesity Treatment Belviq Exceeds US$10 Million Three Weeks after Launch
August 5, 2013
- Astellas’s First-Quarter Net Profit Down 27% Despite Increases in Sales; 5% Decline in Domestic Sales Due to Impact of Generics
August 5, 2013
- MTPC to Consolidate Domestic Manufacturing Plants, Transferring Ashikaga Plant to CMIC Holdings
August 5, 2013
- Apo Plus to Hire 1,000 Contract MRs by 2013-End
August 2, 2013
- Daiichi Sankyo to Cut 400 to 500 Workers in Europe
August 2, 2013
- Daiichi Sankyo Sales Up 4% in First Quarter, Profits Down due to Ranbaxy Business Slump
August 2, 2013
- Takeda April-June Sales Up 3%, but Operating Profit Logs Double-Digit Fall
August 2, 2013
- Sanofi Files NDA for Prostate Cancer Treatment Cabazitaxel in Japan
August 2, 2013
- Prospects for World’s 1st FD Treatment Remain Unclear; Success Will Depend on Raising Awareness, Role of Endoscopy
August 2, 2013
- Pfizer, Takeda Launch RA Treatment Xeljanz, Prepare for Promoting Proper Use of Drug
August 1, 2013
- Takeda Paid 40 billion Yen to Healthcare Professionals in FY2012
August 1, 2013
- 2 Beijing-Based Wholesalers Could Serve as Point of Contact for Japanese Drug Makers: Mr Yoda of Medipal Holdings
August 1, 2013
- PII Study of Renal Anemia Treatment Codeveloped by FibroGen Starts in Japan: Astellas
August 1, 2013
- Sanofi K.K.’s Payments to Healthcare Professionals Total 9.8 Billion Yen in 2012
July 31, 2013
- Ex-Novartis Employee Had Access to Pre-Locked Data: Third-Party Probe
July 31, 2013
- Novartis Paid 23.6 Billion Yen to Doctors, Medical and Research Institutions in 2012
July 31, 2013
- Novartis’s Third-Party Probe Finds “No Evidence” Indicating Data Falsification by Ex-Employee; Truth behind Diovan Woe Not Yet Uncovered
July 30, 2013
- Arbekacin Inhalation Solution Enters PI Study in US: Meiji Seika Pharma
July 30, 2013
ページ
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…